Kura Oncology's stock rose 14.5% following second-quarter results and publication of preclinical data on its FDA-approved menin inhibitor ziftomenib in the journal Blood. Revenue increased to $20.87 million, though net loss widened to $68.33 million. The Blood study showed ziftomenib retained activity against certain resistance-linked MEN1 mutations in leukaemia models, strengthening scientific confidence in the therapy. The drug is marketed as KOMZIFTI for relapsed or refractory NPM1-mutated AML and is being investigated for broader oncology applications. Despite the positive data, Kura remains unprofitable with substantial quarterly losses. Analyst revenue projections for 2029 range widely, from consensus estimates around $353 million to more optimistic forecasts of $861.5 million, reflecting uncertainty about the company's commercial trajectory.

Kura Oncology reported $9.1 million in net product revenue for COMZIFTI in Q2 2026, exceeding internal expectations. The company captured majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market within its second full commercial quarter, despite being second to market. Management attributes the rapid adoption to the product's differentiated profile, including predictable safety and dosing convenience. Physician-initiated combination use accounted for approximately 40% of new patient starts. The company has achieved over 90% engagement with top-priority AML accounts and secured market access covering over 95% of lives. Kura maintained collaboration revenue guidance of $45 million to $55 million for 2026. The pivotal KOMET-017 Phase 3 trial remains on track for top-line results in 2028.

Kura Oncology reported second quarter 2026 financial results, with KOMZIFTI generating $9.1 million in net product revenue, up 57% from the first quarter. The drug also achieved approximately 115 new patient starts, a 35% increase over the previous quarter. KOMZIFTI secured majority share of new patient starts in the relapsed or refractory NPM1-mutant AML menin inhibitor class after two full quarters on the market. The company reported more than 250 total prescriptions in the second quarter, up 59% from the first quarter. Research and development expenses totalled $61.9 million, whilst selling, general and administrative expenses reached $31.8 million. Net loss for the quarter was $68.3 million. As of 30 June 2026, Kura held $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments from Kyowa Kirin.